Etacept 25mg

Etacept (Etanercept) 25mg Injection is a medication used to treat various conditions, including:

• Rheumatoid arthritis (RA)
• Psoriatic arthritis (PsA)
• Juvenile idiopathic arthritis (JIA)
• Plaque psoriasis
• Enthesitis-related arthritis (ERA)
• Ankylosing spondylitis (AS)

Composition: Each injection of Etacept contains 25mg of Etanercept (an active pharmaceutical ingredient), which is a recombinant human tumor necrosis factor (TNF) receptor fusion protein.

Mechanism of Action: Etanercept works by binding to TNF-alpha, a protein that plays a key role in inflammation and immune response. By binding to TNF-alpha, Etanercept inhibits its activity and reduces the inflammation and immune response associated with the conditions it is used to treat.

Dosage: The recommended dose of Etacept varies depending on the condition being treated. For rheumatoid arthritis and psoriatic arthritis, the usual dose is 25mg injected subcutaneously twice a week. For juvenile idiopathic arthritis, the usual dose is 25mg injected subcutaneously once a week. For plaque psoriasis, the usual dose is 25mg injected subcutaneously twice a week for 3 months, followed by 25mg injected subcutaneously every other week.

Side Effects: Common side effects of Etacept include:

• Injection site reactions
• Headache
• Fatigue
• Muscle or joint pain
• Nausea
• Diarrhea
• Rash

Rare but serious side effects include:

• Increased risk of infections, including serious infections such as tuberculosis and sepsis
• Increased risk of lymphoma and other types of cancer
• Increased risk of demyelinating diseases, such as multiple sclerosis and Guillain-Barré syndrome
• Increased risk of autoimmune disorders, such as lupus-like syndrome and vitiligo

Recommendation: Etacept is recommended for patients with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, plaque psoriasis, enthesitis-related arthritis, or ankylosing spondylitis who have not responded to other treatments. Patients with a history of hypersensitivity reactions to Etanercept or other TNF-alpha inhibitors should not receive Etacept.

Important Note:

• Etacept should be used under the guidance of a healthcare provider with experience in the treatment of the condition being treated.
• Patients with a history of liver disease, kidney disease, or other medical conditions that may affect their ability to respond to treatment should be closely monitored while taking Etacept.
• Etacept may interact with other medications, such as immunosuppressants and certain antibiotics. Patients should inform their healthcare provider of all medications they are taking before starting Etacept therapy.
• Patients should be advised to report any symptoms of hypersensitivity reactions, such as rash, itching, swelling, or difficulty breathing.